Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Janet Hampton Explains the Distress Thermometer Study

May 24th 2011

Janet Hampton from the University of Michigan Health System Cancer Center Explains the Distress Thermometer Study

Janet Hampton on the Distress Thermometer Study Results

May 24th 2011

Janet Hampton University of Michigan Health System Cancer Center Explains Distress Thermometer Study Results

FDA Approves Sutent for Pancreatic Cancer

May 23rd 2011

The FDA has approved Sutent (sunitinib) for the treatment of patients with unresectable, locally advanced, or metastatic pancreatic neuroendocrine tumors (pNET)

Janet Hampton Describes the Distress Thermometer

May 23rd 2011

Janet Hampton Describes the Distress Thermometer

Four-Drug Chemotherapy Combo Extends Lives of Patients with Pancreatic Cancer

May 12th 2011

Results from a phase III study showed that the chemotherapy combination FOLFIRINOX nearly doubled the survival time for patients with pancreatic adenocarcinoma

Cancer Cells Outsmarting Smart Bombs: Gastrointestinal Stromal Tumors (GIST)

May 12th 2011

Certain patients whose cancer cells form mutations and build up a resistance to drugs, drive the need for second- and third-line therapies

Oncolytic Viruses Target Pancreatic Stem Cells

May 10th 2011

Oncolytic viruses have the potential of killing cancer stem cells, particularly in cases of potentially fatal pancreatic cancer

FDA Approves Afinitor for Pancreatic Cancer

May 6th 2011

Afinitor is now approved for the treatment of pancreatic neuroendocrine tumors in patients with unresectable, locally advanced, or metastatic disease

Two or More Drinks a Day Increases Colorectal Cancer Risk

May 6th 2011

New data suggest that individuals who drink moderate amounts of alcohol have an increased likelihood of developing colorectal cancer

Speculating Spectrum: More buzz about stock prices than the recently approved Fusilev indication

May 5th 2011

Spectrum Pharmaceuticals stock prices are the biggest story across the internet, not the FDA's approval of Fusilev

Aflibercept Delivers Positive Results in Colorectal Trial

April 29th 2011

Aflibercept, an investigational angiogenesis inhibitor, improved overall survival as a second-line treatment for patients with mCRC

PARP Inhibitors May Help Fight Colon Cancer

April 28th 2011

A class of drugs that has shown encouraging results in breast and ovarian cancers with BRCA gene mutations may also benefit patients who have colorectal cancers

Sunitinib Becomes 2nd Pancreatic Cancer Drug to Gain FDA Panel's Support

April 13th 2011

Pfizer's sunitinib provides a favorable benefit-risk profile in patients with unresectable pancreatic neuroendocrine tumors (pNETs)

FDA Panel Unanimously Supports Use of Everolimus in Pancreatic Cancer

April 12th 2011

After much anticipation the Oncologic Drugs Advisory Committee has returned a verdict on Novartis' everolimus (Afinitor)

Chasing a Breakthrough in Cancer Cell Signaling: An Interview With William G. Cance, MD

March 29th 2011

In 1993, William G. Cance, MD, was the first researcher to clone human focal adhesion kinase (FAK) and demonstrate its overexpression in metastatic cancers.

The Use of Tyrosine Kinase Inhibitors for Gastrointestinal Stromal Tumors (GIST)

March 15th 2011

In this review article, the author discusses the use of tyrosine kinase inhibitors in the management of patients with gastrointestinal stromal tumors.

ASCO GI Coverage: Delaying Chemotherapy Increases the Mortality Risk of Patients with Colon Cancer

March 14th 2011

The results of a systematic review and meta-analysis suggest that the mortality risk for colon cancer patients begins to increase with any avoidable delay in adjuvant chemotherapy beyond 4 weeks.

ASCO GI Coverage: Everolimus Associated With Significant PFS Improvement in Patients With PNETs

March 13th 2011

Data from a large randomized trial showed that treatment with the targeted agent everolimus was associated with a 65% improvement in progression-free survival (PFS) in patients with advanced pancreatic neuroendocrine tumors (PNETs).

Laura Metcalfe on Colorectal Screening

March 12th 2011

Laura Metcalfe, MSN, RN, APN, C, AOCNS Advanced Practice Nurse, GI Division from John Theurer Cancer Center on Colorectal Screening

Laura Metcalfe on the Virtual Colonoscopy

March 12th 2011

Laura Metcalfe, MSN, RN, APN, C, AOCNS Advanced Practice Nurse, GI Division from John Theurer Cancer Center on the Virtual Colonoscopy